When do the patents on SYPRINE expire, and when will SYPRINE go generic?

Sponsor	Phase
University of British Columbia	N/A
Yale University	N/A
Valeant Pharmaceuticals International, Inc.	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	SYPRINE	trientine hydrochloride	CAPSULE;ORAL	019194-001	Nov 8, 1985	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 29, 2026

Syprine is a branded formulation of trientine hydrochloride used to treat Wilson disease. Its commercial trajectory has been shaped by three forces: a small orphan-drug patient population, historically high pricing, and generic competition after FDA approval of trientine hydrochloride capsules. Syprine has limited standalone disclosure in public company filings, so product-level revenue and profitability cannot be separated reliably from broader portfolio results.

What is Syprine and who markets it?

Syprine contains trientine hydrochloride, a copper-chelating agent indicated for patients with Wilson disease who are intolerant of penicillamine. The product is administered as 250-mg capsules and requires specialized handling because the capsules must be protected from heat and stored in the original container.[1]

Product	Active ingredient	Dosage form	Primary indication	Regulatory status
Syprine	Trientine hydrochloride	250-mg capsule	Wilson disease	FDA-approved NDA 018937
Generic trientine HCl	Trientine hydrochloride	250-mg capsule	Wilson disease	FDA-approved ANDAs
Cuvrior	Trientine tetrahydrochloride	Tablet	Wilson disease	FDA-approved in 2022
Cuprior	Trientine tetrahydrochloride	Tablet	Wilson disease	Authorized in Europe

Syprine has been associated with Valeant Pharmaceuticals, now Bausch Health, through the company’s legacy specialty-pharmaceutical portfolio. Bausch Health’s public filings generally report results by operating segment rather than disclosing Syprine revenue separately.[2]

How large is the Syprine market?

The Syprine market is commercially small in patient volume but can generate high revenue per treated patient.

Wilson disease is a rare inherited disorder involving impaired copper elimination. Prevalence estimates vary by geography and methodology, but treatment demand is concentrated among a relatively small population requiring lifelong therapy.[3] The practical market is limited by:

Low diagnosed-patient numbers.
Lifelong treatment duration.
Use of alternative chelators, including penicillamine and zinc.
Treatment switching caused by tolerability, adherence, supply, or insurance coverage.
Limited physician and specialty-pharmacy channels.

Before generic entry, Syprine benefited from orphan-drug economics. A small patient population reduced the commercial need for broad primary-care promotion, while chronic use increased revenue per patient.

The market is structurally different from large primary-care drug categories. Volume growth is constrained, but price changes can materially alter revenue. That made Syprine vulnerable to payer backlash and substitution once lower-priced alternatives became available.

Why did Syprine pricing attract scrutiny?

Syprine became a prominent example of price escalation in a rare-disease medicine. Public reporting documented substantial price increases after rights to the product changed hands, with the annual treatment cost rising sharply from historical levels.[4]

The pricing model was commercially rational from a narrow orphan-drug perspective: a low-volume product with chronic use can support a high list price if reimbursement remains available. The model became less durable as:

Payers increased utilization management.
Patients and advocacy groups challenged affordability.
Generic manufacturers entered the market.
Physicians gained alternative trientine products.
Public scrutiny increased the risk of reputational and policy intervention.

For Syprine, price elasticity was limited at the individual patient level because Wilson disease requires ongoing treatment. At the market level, however, price increases accelerated payer substitution and created an opening for generic manufacturers.

When did Syprine lose market exclusivity?

Syprine’s commercial exclusivity weakened when generic trientine hydrochloride capsules entered the U.S. market. FDA-approved generic versions of trientine hydrochloride capsules created direct pharmaceutical-equivalent competition with the branded product.[5]

The key distinction is between regulatory exclusivity and patent exclusivity:

Protection type	Syprine position
Orphan-drug exclusivity	Historical protection may have applied to the original approval period but is no longer commercially controlling
New chemical entity exclusivity	Expired
Formulation exclusivity	No longer sufficient to prevent generic competition
Orange Book patent barrier	No active patent barrier is generally identified as controlling current generic access
Generic competition	Present
Biosimilar protection	Not applicable because trientine is a small-molecule drug

The relevant commercial loss was therefore not a single patent-expiration event. It was the cumulative erosion of regulatory, market, and pricing protection followed by generic entry.

What is the Orange Book status of Syprine?

Syprine is listed in FDA drug databases under NDA 018937. The Orange Book is the relevant source for identifying approved products, therapeutic-equivalence ratings, and listed patents or exclusivity periods.[6]

For a small-molecule capsule such as Syprine, the most important Orange Book questions are:

Whether the reference product remains actively marketed.
Whether generic products have an AB rating.
Whether any unexpired patents are listed.
Whether the listed product has a current reference-product role for ANDA approvals.
Whether formulation or method-of-use patents constrain substitution.

The commercial record indicates that generic trientine hydrochloride capsules have eroded Syprine’s exclusivity. No current patent estate appears to provide a durable, broad barrier comparable to the protection available for a recently launched specialty medicine.

Which companies are challenging Syprine commercially?

The principal challengers are generic manufacturers rather than biosimilar developers.

Generic trientine hydrochloride manufacturers

FDA-approved generic trientine hydrochloride capsules compete directly with Syprine on active ingredient, strength, dosage form, and indication. Generic competition is likely to focus on:

Acquisition cost.
Formulary placement.
Specialty-pharmacy distribution.
Patient assistance and continuity of supply.
Reimbursement reliability.
Ability to maintain inventory for a rare-disease population.

The number of approved manufacturers can vary over time because ANDA holders may launch, discontinue, or change commercial status. FDA approval alone does not guarantee sustained market presence.

Orphalan and Cuvrior

Orphalan’s Cuvrior, approved by FDA in 2022, adds a branded alternative based on trientine tetrahydrochloride.[7] Cuvrior is not a generic Syprine capsule. It is a different trientine salt and tablet formulation, with its own labeling, dosing instructions, and commercial strategy.

Cuvrior’s competitive position depends on:

Tablet convenience.
Patient adherence.
Physician familiarity.
Payer coverage.
Switching requirements.
Manufacturer support services.
Relative price to Syprine and generic trientine hydrochloride.

What formulations are protected in the trientine market?

The core Syprine formulation is a 250-mg trientine hydrochloride capsule. Its historical commercial value came from the approved product, brand recognition, and market access rather than from a currently dominant formulation patent moat.

Cuvrior uses trientine tetrahydrochloride tablets. The distinction matters because salt form, dosage form, stability, packaging, and administration requirements can create regulatory and commercial differentiation even when products share the same active chelating moiety.

Potential formulation barriers include:

Salt selection.
Tablet versus capsule delivery.
Stability under heat and humidity.
Packaging requirements.
Dose flexibility.
Food and administration instructions.
Manufacturing controls for a low-volume product.

These factors may slow switching but generally do not prevent generic competition against the original trientine hydrochloride capsule.

Are there method-of-use patents or manufacturing barriers?

Method-of-use patents are less likely to provide strong current protection for Syprine than product-specific patents would for a newer drug. Wilson disease treatment with trientine is an established therapeutic use, limiting the commercial value of late-arising use claims unless they cover a narrowly differentiated population, dosing regimen, or treatment sequence.

Manufacturing barriers are more relevant operationally than legally. A manufacturer must maintain:

Reliable supply of trientine hydrochloride.
Validated capsule production.
Stability data and compliant packaging.
Controlled distribution through specialty channels.
Pharmacovigilance capabilities for a chronic rare-disease medicine.

Because the market is small, a generic company may have limited incentive to maintain multiple redundant production lines. That creates potential supply concentration even when several products have regulatory approval.

What is Syprine’s financial trajectory?

Syprine’s financial trajectory has three phases.

Phase 1: Stable orphan-product economics

Before major price increases and generic entry, Syprine had a recurring revenue base supported by chronic therapy and limited competition. Revenue growth depended more on price and patient retention than on new diagnoses.

Phase 2: Price-driven revenue expansion

The product generated greater revenue per patient after major list-price increases. This improved gross-revenue potential but increased payer resistance, public scrutiny, and substitution risk.[4]

The key financial weakness of this phase was that price-led growth was not equivalent to durable demand expansion. The treated population remained small, and higher prices increased the value available to competitors.

Phase 3: Generic erosion and portfolio de-emphasis

After generic trientine hydrochloride entered the market, Syprine faced lower net pricing, formulary pressure, and patient switching. Bausch Health does not generally disclose Syprine sales as a separate reporting line, preventing a precise standalone revenue series.[2]

Financial driver	Effect on Syprine
Chronic lifelong use	Supports recurring demand
Rare-disease population	Limits volume growth
Historical price increases	Increased gross revenue per patient
Generic entry	Reduced price and share
Cuvrior launch	Added branded competition
Specialty distribution	Raises channel complexity
Product-specific disclosure	Limited visibility into revenue and margin

Syprine should therefore be valued as a declining or strategically limited legacy specialty product rather than as a growth asset, unless the manufacturer has a differentiated access strategy or supply advantage.

How much revenue is exposed to generic competition?

Standalone Syprine revenue is not publicly separated in Bausch Health’s reported financial statements. The product’s revenue exposure is therefore best analyzed through market structure rather than a reported product-level figure.

The highest-risk revenue components are:

Patients with commercially insured coverage.
Patients whose plans mandate generic substitution.
Accounts with aggressive specialty-pharmacy controls.
New patients starting trientine therapy.
Patients whose physicians do not require brand continuity.

The more defensible revenue base consists of patients who:

Are stable on branded therapy.
Have favorable brand coverage.
Experience intolerance or practical problems with alternatives.
Receive manufacturer assistance.
Are managed by physicians with established Syprine prescribing patterns.

Even this base is vulnerable if payers impose mandatory substitution or if Cuvrior captures patients seeking a tablet formulation.

What patent litigation affects Syprine?

No major, currently controlling patent-litigation campaign is central to Syprine’s U.S. commercial outlook. The competitive issue is generic and branded substitution, not a high-value patent dispute over a recently launched product.

Paragraph IV litigation would matter if a generic applicant challenged a listed unexpired patent. In Syprine’s case, the commercial market has already moved beyond the period in which a conventional Paragraph IV challenge would determine whether the product remains protected. The relevant risk is execution by generic manufacturers, including supply continuity and payer conversion.

Is there biosimilar risk for Syprine?

Biosimilar risk does not apply. Syprine is a chemically synthesized small-molecule drug, not a biologic. Its competitive pathway is ANDA-based generic substitution rather than the Biologics Price Competition and Innovation Act pathway.

The applicable competitive risks are:

Generic trientine hydrochloride capsules.
Alternative trientine salts.
Alternative dosage forms.
Penicillamine and zinc therapy.
Payer-driven treatment switching.

How does Syprine compare with Cuvrior and generic trientine?

Factor	Syprine	Generic trientine HCl	Cuvrior
Active ingredient	Trientine hydrochloride	Trientine hydrochloride	Trientine tetrahydrochloride
Form	Capsule	Capsule	Tablet
Brand status	Legacy brand	Generic	Branded
Main advantage	Familiarity and continuity	Lower price	Newer formulation and commercial positioning
Main weakness	Price and generic substitution	Limited differentiation	Premium pricing and payer access
Patent value	Limited current barrier	ANDA competition	Potentially stronger formulation positioning
Market role	Established reference brand	Price competitor	Branded alternative

Syprine’s strongest commercial asset is installed-base familiarity. Its weakest asset is lack of a clear price or formulation advantage over competitors.

What generic launch scenarios exist?

Base case

Generic trientine hydrochloride maintains or increases share, while Syprine remains available for patients with brand preference, continuity requirements, or favorable coverage. Net price declines and revenue contracts gradually.

Downside case

Payers impose mandatory generic substitution, multiple generic suppliers compete on price, and Cuvrior captures selected new starts. Syprine becomes a low-volume legacy brand.

Supply-constrained case

One or more generic manufacturers experience supply interruptions. Syprine retains temporary share among patients requiring uninterrupted therapy, although the effect depends on inventory and payer policy.

Differentiation case

The brand retains a narrower patient segment through support services, stable supply, physician familiarity, or coverage exceptions. This scenario supports persistence but not broad market growth.

What is the geographic coverage of Syprine?

Syprine’s most relevant market is the United States, where FDA approval, Orange Book status, payer coverage, and ANDA competition determine commercial performance. Trientine products are also marketed internationally under different brand names, regulatory approvals, and salt formulations.

Geographic value is limited by:

Rare-disease prevalence.
National reimbursement decisions.
Local orphan-drug rules.
Product registration.
Specialty distribution.
Availability of alternative chelators.

U.S. economics historically supported high pricing, but U.S. generic entry also creates substantial revenue erosion because the market has a mature substitution infrastructure.

Key Takeaways

Syprine is trientine hydrochloride 250-mg capsules for Wilson disease.
Its commercial model relied on chronic use, a small patient population, and high revenue per patient.
Major price increases increased short-term revenue potential but accelerated payer and public scrutiny.
Generic trientine hydrochloride capsules have materially weakened Syprine’s exclusivity and pricing power.
Cuvrior adds branded competition through a trientine tetrahydrochloride tablet formulation.
Biosimilar risk is irrelevant because Syprine is a small-molecule drug.
No major current patent-litigation campaign appears to determine Syprine’s market access.
Bausch Health does not separately disclose Syprine revenue, so product-level financial forecasting requires market-share and pricing assumptions.
The most likely trajectory is declining net sales with residual demand from stable patients, brand-preference cases, and supply-related substitution resistance.

FAQs About Syprine Market Dynamics

Is Syprine still available in the United States?

Syprine remains an FDA-approved reference product, but commercial availability and payer coverage can vary. Generic trientine hydrochloride capsules compete directly with the brand.

Is trientine the same as Syprine?

Syprine is a brand of trientine hydrochloride. Other trientine products may use a different salt, such as trientine tetrahydrochloride, or a different dosage form.

Does Medicaid cover Syprine?

Coverage depends on the state Medicaid program, preferred-drug list, prior-authorization rules, and generic-substitution requirements. Coverage for the brand can differ materially from coverage for generic trientine.

Can a patient switch from Syprine to Cuvrior?

A switch may be clinically possible but requires physician oversight because the products use different salts, dosage forms, labeling, and administration instructions.

Is Syprine a growth product for Bausch Health?

Syprine is better characterized as a legacy specialty product exposed to generic erosion than as a growth product. Its standalone contribution is not separately disclosed in Bausch Health’s public financial reporting.

References

U.S. Food and Drug Administration. (2023). Syprine (trientine hydrochloride) capsules prescribing information.
Bausch Health Companies Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
National Organization for Rare Disorders. (2024). Wilson disease.
U.S. Government Accountability Office. (2018). Drug industry: Profits, research and development spending, and merger and acquisition deals.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, trientine hydrochloride capsules.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2022). Cuvrior (trientine tetrahydrochloride) tablets prescribing information.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	3
Patent Applications:	359
Drug Prices:	Drug price information for SYPRINE
What excipients (inactive ingredients) are in SYPRINE?	SYPRINE excipients list
DailyMed Link:	SYPRINE at DailyMed

Drug Class	Metal Chelator
Mechanism of Action	Metal Chelating Activity

AI Deep Research

Questions you can ask:

Summary for SYPRINE

Recent Clinical Trials for SYPRINE

Pharmacology for SYPRINE